“if more countries around the world had reciprocated by allowing UK volunteers to enjoy fully vaccinated status for overseas travel, these measures would not have been necessary.” Novavax stated in June that their vaccine was about 90 percent efficacious against the novel coronavirus following a trial involving more than 30,000 individuals in the United States and Mexico.
Novavax, headquartered in the United States, has requested that the World Health Organization authorize its Covid-19 vaccine for emergency use in order for it to be included in the COVAX global vaccine program. However, it has delayed trying for clearance in Europe and the United States. The Novavax injections are more convenient to store and transport than other choices, and have long been anticipated to play a major role in expanding and boosting vaccination supply in impoverished nations that are eager for additional doses.
